163 related articles for article (PubMed ID: 22337948)
1. HCV genotype-3a T cell immunity: specificity, function and impact of therapy.
Humphreys IS; von Delft A; Brown A; Hibbert L; Collier JD; Foster GR; Rahman M; Christian A; Klenerman P; Barnes E
Gut; 2012 Nov; 61(11):1589-99. PubMed ID: 22337948
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
3. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T
Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700
[TBL] [Abstract][Full Text] [Related]
4. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
5. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
Pillai V; Lee WM; Thiele DL; Karandikar NJ
J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
[TBL] [Abstract][Full Text] [Related]
6. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
[TBL] [Abstract][Full Text] [Related]
7. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
von Delft A; Humphreys IS; Brown A; Pfafferott K; Lucas M; Klenerman P; Lauer GM; Cox AL; Gaudieri S; Barnes E
Gut; 2016 Jan; 65(1):112-23. PubMed ID: 26092843
[TBL] [Abstract][Full Text] [Related]
8. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM
Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023
[TBL] [Abstract][Full Text] [Related]
10. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
11. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
Legrand E; Neau D; Galperine T; Trimoulet P; Moreau JF; Pitard V; Lacut JY; Ragnaud JM; Dupon M; Le Bail B; Bernard N; Schvoerer E; Houghton M; Fleury H; Lafon ME
J Infect Dis; 2002 Aug; 186(3):302-11. PubMed ID: 12134226
[TBL] [Abstract][Full Text] [Related]
12. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection.
Sugimoto K; Kaplan DE; Ikeda F; Ding J; Schwartz J; Nunes FA; Alter HJ; Chang KM
J Virol; 2005 Jun; 79(11):6976-83. PubMed ID: 15890937
[TBL] [Abstract][Full Text] [Related]
13. Evidence of CD4
Lucas M; Deshpande P; James I; Rauch A; Pfafferott K; Gaylard E; Merani S; Plauzolles A; Lucas A; McDonnell W; Kalams S; Pilkinton M; Chastain C; Barnett L; Prosser A; Mallal S; Fitzmaurice K; Drummer H; Ansari MA; Pedergnana V; Barnes E; John M; Kelleher D; Klenerman P; Gaudieri S
Sci Rep; 2018 May; 8(1):7224. PubMed ID: 29740042
[TBL] [Abstract][Full Text] [Related]
14. HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.
Amador-Cañizares Y; Martínez-Donato G; Alvarez-Lajonchere L; Vasallo C; Dausá M; Aguilar-Noriega D; Valenzuela C; Raíces I; Dubuisson J; Wychowski C; Cinza-Estévez Z; Castellanos M; Núñez M; Armas A; González Y; Revé I; Guerra I; Pérez Aguiar A; Dueñas-Carrera S
World J Gastroenterol; 2014 Jan; 20(1):148-62. PubMed ID: 24415868
[TBL] [Abstract][Full Text] [Related]
15. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus.
Rigopoulou EI; Abbott WG; Williams R; Naoumov NV
Antiviral Res; 2007 Jul; 75(1):36-42. PubMed ID: 17210188
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.
Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Márquez-Galán JL; Núñez-Roldán A; Aguilar-Reina J
Liver Int; 2014 Jul; 34(6):e80-8. PubMed ID: 24127783
[TBL] [Abstract][Full Text] [Related]
17. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
[TBL] [Abstract][Full Text] [Related]
18. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response.
Sugimoto K; Stadanlick J; Ikeda F; Brensinger C; Furth EE; Alter HJ; Chang KM
Hepatology; 2003 Mar; 37(3):590-9. PubMed ID: 12601357
[TBL] [Abstract][Full Text] [Related]
19. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
Burchill MA; Golden-Mason L; Wind-Rotolo M; Rosen HR
J Viral Hepat; 2015 Dec; 22(12):983-91. PubMed ID: 26482547
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
